Showing 8311-8320 of 9116 results for "".
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowthhttps://practicaldermatology.com/news/alopecia-areata-breakthrough-two-studies-suggest-jak-inhibitors-may-spur-hair-regrowth/2458427/Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citrate) for rheumat
- African-American Organ Transplant Recipients at Risk for Skin Cancerhttps://practicaldermatology.com/news/african-american-organ-transplant-recipients-at-risk-for-skin-cancer/2458428/All organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer, according to researchers from Drexel University College of Medicine in Philadelphia. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- National Rosacea Society Awards Three New Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-three-new-grants/2458430/The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an associate professor of dermatology at Johns Hopk
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- ModiFace Launches AI-Based Live-Video Skin Simulation Technologyhttps://practicaldermatology.com/news/modiface-launches-ai-based-live-video-skin-simulation-technology/2458437/ModiFace, a provider of augmented reality technology for the beauty and medical industries, unveiled an artificial intelligence (AI) based video editing technology that can realistically simulate skin transformations in live video. The new Skin AI technology, which has been created with the
- US FDA Grants Orphan Drug Status to TXA127 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/us-fda-grants-orphan-drug-status-to-txa127-for-recessive-dystrophic-epidermolysis-bullosa/2458442/The U.S. Food and Drug Administration has granted Orphan Drug Status to TXA127 as a potential treatment for the rare genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). TXA127 developer, Tarix Orphan LLC
- Sensus Healthcare Receives Frost & Sullivan 2016 Global NMSC Therapy Technology Leadership Awardhttps://practicaldermatology.com/news/sensus-healthcare-inc-receives-frost-sullivan-2016-global-nmsc-therapy-technology-leadership-award/2458443/Sensus Healthcare, Inc. has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Tec